Europe To Resume AZ Vaccine Use After Safety Review, But Confidence Knocked
Rare But Serious Events Being Monitored
Executive Summary
The EMA’s conclusions are in line with those of the UK regulator and the World Health Organization, but EU countries’ stop-start decisions will have done nothing to boost the public’s trust in the vaccine.
You may also be interested in...
EMA Using Real World Data To Assess Safety Of COVID-19 Vaccines
The EMA is investigating possible links between the three COVID-19 vaccines currently being used in Europe and cases of thrombotic events. It is also planning safety studies in targeted populations.
EU Explains Plans To Speed Up Variant Vaccine Approvals
The EU institutions are taking steps to preserve the effectiveness of existing vaccines in the face of mutations in the SARS-CoV-2 virus.
AstraZeneca Vaccine’s ‘Big Gap’: DSMB Questions Results Released By Firm In Latest Controversy
‘Harsh note’ from Data Safety and Monitoring Board follows AstraZeneca press release that contained incomplete information about the Phase III US trial for its COVID vaccine. It remains to be seen how the company will fix this ‘unforced error’ and weather the latest threat to public trust.